62P A multi-center real-world study of the efficacy and safety of PARP inhibitors in patients with ovarian cancer in Spain
Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Ainhoa Madariaga(Hospital Universitario 12 De Octubre), César Gómez-Raposo(Hospital Universitario Infanta Sofía), C. Maximiano Alonso(Hospital Universitario Puerta de Hierro Majadahonda), Arántzazu Barquín(Hospital Universitario HM Sanchinarro), Gloria Marquina(Hospital Clínico San Carlos), M. Simon(Hospital General Universitario de Ciudad Real), Sara Ramírez(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), C. Pernaut Sanchez(Hospital Universitario Severo Ochoa), A. Gallego Martínez(Clinica Universidad de Navarra), Manuel I. Gallego(Hospital Universitario de Móstoles), Alfonso Cortés Salgado(Hospital Universitario Ramón y Cajal), R. Cervera Calero(Hospital Universitario del Henares), E. Bernal Hertfelder(Research Institute Hospital 12 de Octubre), A. Ramchandani Vaswani(Hospital Universitario Insular de Gran Canaria), A. M. García Tapiador(Complejo Hospitalario Universitario de Toledo)
Cited by 0
Related Papers
Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry
|British Journal of Cancer|2017|106
Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer
|JAMA Oncology|2024|77
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
|Nature Communications|2023|65
Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry
|European Journal of Surgical Oncology|2018|60
Chronic opioid therapy in long-term cancer survivors
|Clinical & Translational Oncology|2016|59